Business
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 13, 2025. Altimmune management will host a conference call at 8:30 am E.T. on May 13 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors. Particip
About this update from Altimmune, Inc.
[{"type":"image","alt":"Altimmune, Inc","displaySize":"","headline":null,"caption":"Altimmune, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":82,"url":"https://media.zenfs.com/en/globenewswire.com/767e25bad8979b96701d6a099286a009"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gY.Kxe7ML79dI0xW5370RA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/767e25bad8979b96701d6a099286a009","width":150,"height":82}},"lazy":false},{"type":"text","content":"GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 13, 2025.","length":234,"tagName":"p"},{"type":"text","content":"Altimmune management will host a conference call at 8:30 am E.T. on May 13 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.","length":256,"tagName":"p"},{"type":"text","content":"Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.","length":237,"tagName":"p"},{"type":"text","content":"About Altimmune","length":15,"tagName":"p"},{"type":"text","content":"Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH, alcohol use disorder as well as alcohol related liver disease. For more information, please visit www.altimmune.com.","length":368,"tagName":"p"},{"type":"text","content":"Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter","length":67,"tagName":"p"},{"type":"text","content":"Company Contact:Greg WeaverChief Financial OfficerPhone: [email protected]","length":89,"tagName":"p"},{"type":"text","content":"Investor Contact:Lee RothBurns McClellanPhone: [email protected]","length":80,"tagName":"p"},{"type":"text","content":"Media Contact:Jake RobisonInizio Evoke, BiotechPhone: 619-849-5383Jake....